![Frontiers | Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial | Medicine Frontiers | Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial | Medicine](https://www.frontiersin.org/files/MyHome%20Article%20Library/566160/566160_Thumb_400.jpg)
Frontiers | Head-to-Head Comparison of Etanercept vs. Adalimumab in the Treatment of Ankylosing Spondylitis: An Open-Label Randomized Controlled Crossover Clinical Trial | Medicine
![تويتر \ Dr T ² | 🙈 🙉 🙊 على تويتر: "Found this gem while going through old records: denial of Humira for #Crohns because it was deemed experimental. Forced me into تويتر \ Dr T ² | 🙈 🙉 🙊 على تويتر: "Found this gem while going through old records: denial of Humira for #Crohns because it was deemed experimental. Forced me into](https://pbs.twimg.com/media/DmqXXG8XcAANZ8-.jpg:large)
تويتر \ Dr T ² | 🙈 🙉 🙊 على تويتر: "Found this gem while going through old records: denial of Humira for #Crohns because it was deemed experimental. Forced me into
![PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial](https://d3i71xaburhd42.cloudfront.net/1f3ea24e842b7750dfbe6b098b7b1b52e074980f/5-Figure1-1.png)
PDF] Comparison of the Efficacy and Safety of Adalimumab (Humira) and the Adalimumab Biosimilar Candidate (HS016) in Chinese Patients with Active Ankylosing Spondylitis: A Multicenter, Randomized, Double-Blind, Parallel, Phase III Clinical Trial
![Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/b843afb8-6390-4599-a869-52d0e3f1e194/gr1.jpg)
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator- controlled phase 3 trial - The Lancet
![Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/4676ad7f-c189-43bf-9107-8362d2fe85ed/gr1.jpg)
Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring - Gastroenterology
![Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/8410494b-6312-4f66-ac2d-ac946fe92b82/jde15533-fig-0001-m.jpg)
Adalimumab in Japanese patients with active ulcers of pyoderma gangrenosum: Twenty‐six‐week phase 3 open‐label study - Yamasaki - 2020 - The Journal of Dermatology - Wiley Online Library
![A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs13075-018-1676-y/MediaObjects/13075_2018_1676_Fig1_HTML.png)
A comparative clinical study of PF-06410293, a candidate adalimumab biosimilar, and adalimumab reference product (Humira®) in the treatment of active rheumatoid arthritis | Arthritis Research & Therapy | Full Text
![Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram](https://www.researchgate.net/profile/Maria-Delgado-Charro/publication/348149033/figure/tbl1/AS:986014956941317@1612095693605/Phase-III-clinical-trials-conducted-for-adalimumab-biosimilars-data-taken-from-16-N_Q640.jpg)
Phase III clinical trials conducted for adalimumab biosimilars; data... | Download Scientific Diagram
![Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2017/09/Paper_65902_abstract_95696_0.png)
Long-Term Safety of Adalimumab (HUMIRA) in Adult Patients from Global Clinical Trials across Multiple Indications: An Updated Analysis in 29,987 Patients Representing 56,951 Patient-Years - ACR Meeting Abstracts
![Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review](http://www.drugtargetreview.com/wp-content/uploads/shutterstock_67707346.jpg)
Abbvie initiates new clinical trial to evaluate humira® (adalimumab) for the treatment of fingernail psoriasis - Drug Target Review
![Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/187f95ea-8461-4f48-b520-76ec27dde966/gr5_lrg.jpg)